The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Deep Learning for Drug Design: an Artificial Intelligence Paradigm for Drug Discovery in the Big Data Era
Open accessAbstract
Over the last decade, deep learning (DL) methods have been extremely successful and widely used to develop artificial intelligence (AI) in almost every domain, especially after it achieved its proud record on computational Go. Compared to traditional machine learning (ML) algorithms, DL methods still have a long way to go to achieve recognition in small molecular drug discovery and development. And there is still lots of work to do for the popularization and application of DL for research purpose, e.g., for small molecule drug research and development. In this review, we mainly discussed several most powerful and mainstream architectures, including the convolutional neural network (CNN), recurrent neural network (RNN), and deep auto-encoder networks (DAENs), for supervised learning and nonsupervised learning; summarized most of the representative applications in small molecule drug design; and briefly introduced how DL methods were used in those applications. The discussion for the pros and cons of DL methods as well as the main challenges we need to tackle were also emphasized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Cortes, C., & Vapnik, V. (1995) · Machine Learning · doi:10.1007/bf00994018 · Cited by 59,421
Gradient-based learning applied to document recognition
Lecun, Y., Bottou, L., Bengio, Y., & Haffner, P. (1998) · Proceedings of the IEEE · doi:10.1109/5.726791 · Cited by 58,805
ImageNet Large Scale Visual Recognition Challenge
Russakovsky, O., Deng, J., Su, H., Krause, J., Satheesh, S., Ma, S., Huang, Z., Karpathy, A., Khosla, A., Bernstein, M., et al. (2015) · International Journal of Computer Vision · doi:10.1007/s11263-015-0816-y · Cited by 39,380
(2014) · Cited by 33,419
Learning representations by back-propagating errors
Rumelhart, D. E., Hinton, G. E., & Williams, R. J. (1986) · Nature · doi:10.1038/323533a0 · Cited by 31,892
Advances in neural information processing systems 7
Cios, K., & Shields, M. (1997) · Neurocomputing · doi:10.1016/s0925-2312(97)90018-7 · Cited by 22,059
Reducing the dimensionality of data with neural networks
Hinton, G. E., & Salakhutdinov, R. R. (2006) · Science · doi:10.1126/science.1127647 · Cited by 20,928
GAN(Generative Adversarial Nets)
(2017) · Journal of Japan Society for Fuzzy Theory and Intelligent Informatics · doi:10.3156/jsoft.29.5_177_2 · Cited by 19,270
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“Moreover, with the advent of ML-based tools, it has become relatively easier to determine the three-dimensional structure of a target protein, which is a critical step in drug discovery, as novel drugs are designed based on the three-dimensional ligand biding environment of a protein [72, 73].”
BackgroundNatural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,241
Recent advances and applications of deep learning methods in materials science
Choudhary, K., DeCost, B., Chen, C., Jain, A., Tavazza, F., Cohn, R., Park, C. W., Choudhary, A., Agrawal, A., Billinge, S. J. L., et al. (2022) · npj Computational Materials · doi:10.1038/s41524-022-00734-6 · Cited by 1,172
A drug-likeness toolbox facilitates ADMET study in drug discovery
Jia, C.-Y., Li, J.-Y., Hao, G.-F., & Yang, G.-F. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.10.014 · Cited by 547
Big data and artificial intelligence modeling for drug discovery
Zhu, H. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023324 · Cited by 455
Metadata
- Authors
- Jing, Y., Bian, Y., Hu, Z., Wang, L., & Xie, X.-Q. S.
- Venue
- The AAPS Journal
- Published
- 2018-03-30
- Volume
- 20
- Issue
- 3
- Pages
- 58-58
- ISSN
- 1550-7416 (ISSN-L)
- OpenAlex
- W2795068716
- Cited by
- 351
- References
- 73
- FWCI
- 25.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deep Learning for Drug Design: an Artificial Intelligence Paradigm for Drug Discovery in the Big Data Era. https://app.cochat.ai/papers/10.1208/s12248-018-0210-0
- The paper
- Jing, Y., Bian, Y., Hu, Z., Wang, L., & Xie, X.-Q. S. (2018). Deep Learning for Drug Design: an Artificial Intelligence Paradigm for Drug Discovery in the Big Data Era. The AAPS Journal. https://doi.org/10.1208/s12248-018-0210-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.